ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
456.83M
Enterprise Value 3
200.99M
Trailing P/E
N/A
Forward P/E 1
-2.33
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
1.78
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-1.25

Trading Information

Stock Price History

Beta (3Y Monthly) 1.13
52-Week Change 3-50.61%
S&P500 52-Week Change 38.78%
52 Week High 320.08
52 Week Low 36.75
50-Day Moving Average 38.60
200-Day Moving Average 310.87

Share Statistics

Avg Vol (3 month) 31.1M
Avg Vol (10 day) 3599.08k
Shares Outstanding 555.17M
Float 47.26M
% Held by Insiders 112.40%
% Held by Institutions 178.69%
Shares Short (Sep 30, 2019) 48.9M
Short Ratio (Sep 30, 2019) 47.66
Short % of Float (Sep 30, 2019) 423.23%
Short % of Shares Outstanding (Sep 30, 2019) 416.13%
Shares Short (prior month Aug 30, 2019) 46.3M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-28.03%
Return on Equity (ttm)-47.76%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-132.17M
EBITDA -161.48M
Net Income Avi to Common (ttm)-154.55M
Diluted EPS (ttm)-2.81
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)285.3M
Total Cash Per Share (mrq)5.17
Total Debt (mrq)22.83M
Total Debt/Equity (mrq)8.89
Current Ratio (mrq)8.86
Book Value Per Share (mrq)4.65

Cash Flow Statement

Operating Cash Flow (ttm)-120.51M
Levered Free Cash Flow (ttm)-68.77M